Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DHODH | Q02127 | 12/20 | 0.44 |
| ▸ | GCGR | P47871 | 1/20 | 0.41 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | PPARG | P37231 | 1/20 | 0.36 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL945897 | 0.86 | GCGR (0.55) | DHODHGCGRRXFP1MAPTTP53 | |
| SCHEMBL3589 | 0.83 | ALDH1A1 (0.44) | GCGRMAPTTP53ALDH1A1L3MBTL1 | |
| SCHEMBL10153184 | 0.82 | GCGR (0.43) | DHODHGCGRPDE10A | |
| SCHEMBL6082682 | 0.81 | ADORA2A (0.44) | DHODHGCGRPDE10A | |
| SCHEMBL27519225 | 0.81 | DHODH (0.45) | DHODHRXFP1MAPTALDH1A1L3MBTL1 | |
| SCHEMBL945299 | 0.80 | GCGR (0.57) | GCGR | |
| SCHEMBL7920817 | 0.79 | GCGR (0.46) | GCGRALDH1A1L3MBTL1CYP2C19 | |
| SCHEMBL10433875 | 0.79 | HMGCR (0.48) | DHODHGCGRMAPTTP53ALDH1A1 | |
| SCHEMBL10434011 | 0.79 | HMGCR (0.44) | DHODHGCGRALDH1A1PDE10A | |
| SCHEMBL28300700 | 0.79 | ADORA1 (0.47) | DHODHGCGRPDE10A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2012013325-A1 | PROCESS FOR THE PREPARATION OF KEY INTERMEDIATES FOR THE SYNTHESIS OF STATINS OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF | LEK PHARMACEUTICALS D.D. (SI) | 2012-02-02 | — | — | WO | disclosed |